Warts Therapeutics Market to Exceed USD 2.5 billion by 2030, Garnering 3.0% CAGR Says, Transparency Market Research
September 25, 2023 05:37 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The warts therapeutics market was estimated to have acquired US$ 1.92 billion in 2018. It...
Dermatology Devices Global Market Report 2023: Increasing Prevalence of Skin Cancer and Other Conditions Fuels Demand
March 24, 2023 07:08 ET
|
Research and Markets
Dublin, March 24, 2023 (GLOBE NEWSWIRE) -- The "Dermatology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global dermatology devices market grew...
Global Dermatoscope Market Report to 2027 - by Product, Technology, Modality, Application, End-user and Region
February 03, 2023 09:48 ET
|
Research and Markets
Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Global Dermatoscope Market by Product, Technology, Modality, Application, End-user, Region: Competition Forecast and Opportunities to 2027" report has...
Dermatology OTC Medications Market Worth $21.31Bn, Globally, by 2028 at 4.7% CAGR - Exclusive Report by The Insight Partners
March 25, 2022 06:46 ET
|
The Insight Partners
New York, March 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology OTC Medications Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Global Light Activated Therapies Market 2021-2030: Over 635 Patents have been Filed/Granted in Past 3 Years
November 26, 2021 05:28 ET
|
Research and Markets
Dublin, Nov. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Light Activated Therapies Market: Distribution by Target Indications, Key Players and Geographies: Industry Trends and Global Forecasts,...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
January 25, 2018 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical...
Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
October 18, 2017 07:05 ET
|
Novan, Inc.
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
March 02, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the...
Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
March 01, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company’s...